Under construction – not a live service
Sign in
Not yet taking people in Saudi ArabiaNo phase

Tranexamic acid to reduce bleeding during weight-loss surgery in people with obesity

Tests tranexamic acid to reduce bleeding during weight-loss surgery in adults with obesity.

Plain-language title generated from the registry record
Registry title: Intravenous Tranexamic Acid

Key facts

Where
Ha'il, Saudi ArabiaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT07192640, who can take part

Where in Saudi Arabia

  • King Salman Specialist Hospital, Hail, KSAHa'il, Saudi ArabiaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ain Shams University
Trial code
NCT07192640
Record updated
25 September 2025
Original description
Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.Read full original descriptionShow less

PERIOPERATIVE USE OF INTRAVENOUS TRANEXAMIC ACID FOR HIGH BMI PATIENTS GOING THROUGH BARIATRIC SURGERIES

Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.

Inclusion: High-risk patients, with obesity, BMI more than 45,; Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.

Exclusion: patients with active thromboembolic disorders; Patients with preexisting renal dysfunction,.

ClinicalTrials.gov NCT07192640